Early badge collection will be available on April 9th, 5-6 p.m.

Day 1- please make sure to arrive at the venue in advance to collect your badges, long lines will delay your attendance for the  first session.

Create your personal agenda –check the favourite icon

08:40
Conference pass

Zika Virus: An update on the disease and the search for a vaccine

Keynotes
09:05
Conference pass

Regulating vaccines at the FDA: Development and licensure of Zika vaccines

Keynotes
09:30
Conference pass

Priorities for linking new vaccine development with public health in low and middle income countries: WHO’s perspective

Keynotes
09:55
Conference pass

The future of vaccine development, covering universal flu and challenging pathogens

Keynotes
11:20
Conference pass

INTERACTIVE ROUNDTABLES

Keynotes
Covering a number of hot topics and delivered by patient groups, sponsors and leading solution providers, choose which two roundtable discussions you would like to join, for ‘off the beaten track’ learning and information you can’t find online. Each session will last 40 minutes so you can join two discussions in the allotted time. The same roundtables will be run twice back to back.

Practical and operational issues around the execution of vaccine trials from a site and sponsor perspective
Adam Larrabee, President, Rochester Clinical Research, Inc
Dr Gray Happner, CMO, NewLink Genetics


Insights in International Alliance for Biological Standardization(IABS) and WHO discussions for successful regulatory use of challenge studies 

Bruno Speder, Head Clinical Regulatory Affairs, Head Registration & Post Marketing Regulatory Affairs, SGS Life Sciences

Best practices for a successful CRO/Pharma partnership for vaccine clinical studies

Lynlee Burton, Director of Project Delivery, PRA Health Sciences

Managing your cold chain – Lessons learned from the Ebola clinical trials
Daniel J. Littlefield, CFO, Principal, Modality Solutions

Gaining a lead on infectious diseases: Building a global bio-intelligence-network and repository

Dr Leslie Lobel, Senior Medical Advisor – Medical Expert Office, ClinicalRM

Clinical Development & trials: Conducting clinical trials in low resource settings
Karen McCarthy, Senior Director of Project Management, PPD Vaccines

Combatting emerging viruses in a globalising world

Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover

Discovering pre-clinical genomic biomarkers of safety and efficacy in vaccine research, design and development

Dr I-Ming Wang, Associate Scientific Director, Principal Scientist, Molecular Profiling Site Lead, Merck & Co.

Round 1: Can we better characterize Glycoconjugate vaccines?
Round 2: Do we need a "Conjugate Vaccine Industry Forum"?

Dr Basav Ghosh, Senior Director, Manufacturing Sciences and Technology & Dr Bo Arve, Executive Director, BioPharmaceutical Sciences, Pfizer

Successful approaches to the conduct of global clinical vaccine studies
Cindy Dukes, VP, Global Project Management, ICON Clinical Research


From start-up to MTA with big pharma: Establishing patents, preclinical functional biomarkers, and development check points
Dr Michael Vajdy, Co-founder, Principal and CSO. EpitoGenesis, Inc.

Why are the antivaxxers winning and how can they be stopped?

Dr Peter Hotez, President of the Sabin Vaccine Institute & Dean of National School of Tropical Medicine, Baylor College of Medicine

Factors of importance for Biotechs to use in identifying, prioritizing and financing new vaccine targets
Dr Peter Nara, President & Chief Executive Officer, Biological Mimetics

Addressing the need for rapid sample sharing during emerging infectious disease outbreaks – lessons from the Zika outbreak
Dr Mukul Ranjan, Senior Advisor for Innovation and Technology Transfer, Technology Transfer and Intellectual Property Office, NIAID  

Adjuvants and technology advancements driving vaccine R&D
Dr Michel De Wilde, Former Senior Vice President R&D of Sanofi Pasteur & Owner, MDW Consultant LLC

Computational vaccinology - immune engineering vaccines
Dr Anne De Groot, CEO/CSO, EpiVax
 
14:10
Conference pass

Plenary discussions with KOLs: Vaccines for the Under-Developed World: Efforts to develop an international fund to develop vaccines that are of low commercial interest but potentially epidemic-proof

Keynotes
  • Creating a new strategy: How does the current global outbreak response system need to change?
  • Innovative ways of gaining vaccine funding
  • How do we know which vaccines to stockpile?
  • How should pharma and industry respond to developing low income vaccines?
15:10
Conference pass

Systems Vaccinology: Enabling rational vaccine design with systems based approaches

Keynotes
  • What is the future for personalized vaccines and medicines?
  • How does the current approaches help us understand the immune system and its response to vaccines and disease
  • The need for immune profiling to be an integrated part of vaccine design and development
15:40
Conference pass

How will recent breakthroughs in immuno-oncology determine cancer vaccine and combinational treatments?

Keynotes
  • The significance of check point inhibitors, oncolytic viruses neoantigens, CAR-T cells and ACT on cancer immunotherapy progress
  • Supporting evidence from combinational studies
  • The role of cancer vaccines in the future of combinational approaches
16:50
Conference pass

Bexsero : Real world experience and future perspectives - A journey from pre-licensure immunogenicity data to post-licensure use of the vaccine

Keynotes
  • The first-of-its-kind vaccination push led to a 50% reduction in meningitis B cases after 10 months
Dr Kumaran Vadivelu, Medical Director, Global Medical Lead, Meningococcal Vaccines, GSK Vaccines
17:15
Conference pass

Vaccines for the Elderly and Immunosenescent

Keynotes
  • How vaccines varying rates of effectiveness is effecting adult immunization rates
  • Vaccination rates for children have steadily risen whilst rates for older adults getting flu, pneumonia, tetanus or shingles shots have stayed stubbornly flat 
  • Leaving millions of older adults at risk of dying, being hospitalized, or, in the case of shingles, suffering debilitating effects that can last years
17:40
Conference pass

Biotechnology and vaccinology - A productive partnership

Keynotes
  • The impact of platform technologies on vaccinology
  • How does long term investment into a given platform generates new opportunities once the technology has matured

Create your personal agenda –check the favourite icon

09:00
Conference pass

Chair’s opening remarks

Bioprocessing & Manufacture
   
09:00
Conference pass
09:00
Conference pass
09:00
Conference pass

Chair’s opening remarks

Emerging Diseases
09:00
Conference pass

Chair’s opening remarks

Veterinary
Dr cyrilCyril G Gay, Senior National Program Leader, A.R.S. National Programs
09:10
Conference pass

An overview of progressive updates from the NIAID-supported Human Immunology Project Consortium (HIPC)

Immune Profiling
  • HIPC goals and funding history
  • Sharing community resources that have been generated by the HIPC
  • HIPC current status future plans
09:10
Conference pass

Using CAR T-cells to target hematologic malignancies and in solid tumors to demonstrate the possibility to design immunity at will for therapeutic application

Cancer & Immunotherapy
  • Progress of chimeric antigen receptor (CAR) T-cells targeting CD19 on B-cells leukemias and lymphomas
  • Inducing durable complete responses in patients who are relapsed or refractory to all other available treatments 
  • Targeting new targets in hematologic malignancies and in solid tumors
09:10
Conference pass

How new drivers of infectious diseases are changing the way we handle NTDs

Emerging Diseases
  • Geographic significance: How NTDs are no longer limited to poverty driven areas only
  • Bringing together  the G20 countries to tackle this globally
09:10
Conference pass

Progress reports: Clinical updates on a next generation RSV mAb and an RSV Vaccine for older adults

Influenza and Respiratory
  • Update the progress of MEDI8897 as it enters Ph IIb studies in infants and 2) Discuss the
  • Ph IIb data of MEDI7510 an RSV vaccine for a older adults
09:10
Conference pass

Defining vaccine failure and addressing the many factors behind it

Clinical Development April 11
  • What do we mean by vaccine failure?
  • What are the factors that have to be in place before we conclude a vaccine “failed"
  • Looking at both immunogenicity and vaccine efficacy
09:10
Conference pass

Designing and building the next generation of vaccine adjuvants

Bioprocessing & Manufacture
  • Key attributes necessary to generate well characterized adjuvant formulations
  • Vaccine/Adjuvant Delivery Issues & Systems
09:10
Conference pass

Collaborative innovation: a strategic imperative for small and large vaccine companies

Veterinary
09:40
Conference pass

Probing the human immune system with vaccines

Immune Profiling
  • Understand the Microbiome and its interaction with the immune system
  • How to effectively manipulate the microbiome to improve efficacy of immunotherapy
  • Potential opportunities and current challenges
09:40
Conference pass

An adenovirus vector based vaccine, expressing F antigen: Protecting young infants against RSV, by eliciting high titer, potent neutralising antibodies and T-cell immunity

Influenza and Respiratory
  • Recombinant human adenoviral Ad26 and Ad35 vectors encoding the RSV F gene have the potential to provide broad and durable protection against RSV in human
  • Evaluating the safety, tolerability and immunogenicity
09:40
Conference pass

How have we handled the Zika outbreak and what prevention measures have we taken as Zika continues to spread in the US?

Emerging Diseases
  • How long until we are likely to be able to vaccinate vulnerable people that are most at risk?
  • Have we responded quickly enough?
  • What about the Zika virus we now understand and what prevention measure have been implemented to mitigate risks
09:40
Conference pass

Future of adjuvants – what is needed? Better strategy for a rational design

Clinical Development April 11
  • Improving the safety database and performance characteristics of QS-21, one of the leading adjuvant candidates
  • manufacturing sustainable source of synthetic QS-21 for vaccine development and trials
09:40
Conference pass

Personalized cancer vaccines that target patients-specific mutations – a reality?

Cancer & Immunotherapy
  • Neoantigen identification
  • Platforms amenable for neoantigen vaccination
  • Review of the recent clinical trial data  in the field of neoantigen vaccines
09:40
Conference pass

Examining legislation on veterinary vaccination and global practices for animal vaccination

Veterinary
 
  • Redefining the role of public sector and private sector veterinarians and technicians
  • Highlighting models of synergies between public and private sector veterinarians for animal vaccination
  • Epizootic diseases vaccination campaigns
  • Discussing mandates provided by the public sector to private veterinarians for vaccination campaigns
Dr Bernard Vallat, Honorary Director General, Office International Des Epizooties
09:40
Conference pass

New compounds to improve the quality/stability of viral antigens in vaccine formulation

Bioprocessing & Manufacture
  • An innovative proprietary surfactant and detergent based approach consisting either on facilitating splitting of native viruses, fragmentation of bacteria, monitoring the solubilization and the stabilization of viral antigens without mutagenesis, truncation and fusion
  • Applying this to solubilize and stabilize functional tetramers of Matrix 2 ion channel from MDCK infected cells
  • Reporting a striking stabilization effect on native HIV envelop protein / spikes in favor of functional stem-exposed conformation as shown by neutralizing antibodies and GP41 interactions, mainly at the membrane proximal external region 
10:10
Conference pass

Developing a representative human translational immune model

Immune Profiling
 
  • Using predictive models to accurately assess human immune responses
  • Challenges and benefits of using a translational immune model over an animal model
10:10
Conference pass

The renaissance of cancer immunotherapies: Biomarker strategies for T-cell therapies

Cancer & Immunotherapy
10:10
Conference pass
10:10
Conference pass

Developing vaccines for emerging diseases: Addressing Zika, MERS and Ebola

Emerging Diseases
  • Role of validated platforms in rapidly addressing emerging infectious diseases – safety and speed of development
  • Generating high level of immune responses in animal models and demonstrating challenge efficacy
  • Results from the first in human studies on safety and immunogenicity
10:10
Conference pass

Encouraging results from clinical studies for a HIV vaccine

Clinical Development April 11
  • The need for better animal models to improve HIV vaccine development
  • The effects of changing a single amino acid in the envelope coat protein of naturally occurring HIV strains
  • Overview of clinical trials and vaccine platforms
Dr Frank Tomaka, Senior Director, Clinical Lead HIV/STI Vaccines, Janssen Infectious Diseases and Vaccines
10:10
Conference pass

Monitoring VLP production using The ViroCyt 3100 Virus Counter

Bioprocessing & Manufacture
10:10
Conference pass

Enabling the One Health concept through enhanced communication and collaboration between human and animal health

Veterinary
11:40
Conference pass

Combinatorial Immunotherapy: Expanding Horizons with DART® Molecules

Immune Profiling
11:40
Conference pass

The RSV F Nanoparticle Vaccine for Infants via Maternal Immunization in Phase 3: Rationale and Update

Influenza and Respiratory
11:40
Conference pass

Use of biomarkers and immunotherapy in cancer and combinational studies

Cancer & Immunotherapy
  • The rationale of combining biomarkers and checkpoint inhibitors with vaccines and oncolytics
11:40
Conference pass

Dry powder vaccine stabilization and delivery by spray drying

Bioprocessing & Manufacture
  • Methods and considerations for Spray dried macromolecules
  • Different Delivery Routes and their application to spray drying
  • Enteric Capsules for oral delivery and rapid pre-clinical development
  • Case Studies
11:40
Conference pass

Collaboration on Government Funded Vaccines Studies

Clinical Development April 11
Senior representative, PRA Health Sciences
11:40
Conference pass

Alleviating disparities between animal and human adjuvanted vaccines

Veterinary
 
  • One health perspective on how to exploit human and veterinary vaccines for therapeutic and preventative treatment across all species
  • Measuring efficacy, toxicity and correlates of protection
  • The future of adjuvants in preclinical and clinical development
11:40
Conference pass

Addressing vaccine development against emerging mosquito-transmitted diseases

Emerging Diseases
  • Building on key competencies from a successful bench to market development of a Japanese Encephalitis vaccine
  • Valneva’s vaccine candidates against Zika, Chikungunya and Yellow fever
11:55
Conference pass

The development of an mRNA vaccine against Zika virus

Emerging Diseases
12:10
Conference pass

How immuno-oncology combinations utilizing a multi-antigen vaccine could enhance immune checkpoint therapy benefits

Immune Profiling
  • Novel therapeutic vaccines drive antigen specific tumor-infiltrating lymphocytes to unlock clinical benefits in patients with poor checkpoint therapy prognosis
  • Immune profiling methods on patient derived samples validate the mechanism of action for the combination approach
  • Two platforms, three products focused on synergistic combination therapies in oncology
12:10
Conference pass

Personalized cellular therapeutic cancer vaccines: What you start with can make all the difference

Cancer & Immunotherapy
  • Overcoming the technical challenges that hinder delivery of vaccine antigens into dendritic cells (DCs)
  • How DCs can be targeted precisely and effectively in vivo using intravenously administration
12:10
Conference pass

Working with government and industry partners to tackle biodefence diseases and our efforts in developing a vaccine against Zika

Emerging Diseases
12:10
Conference pass

Developing an HSV vaccine to control clinical recurrences and viral shedding

Clinical Development April 11
12:10
Conference pass

Application of analytical and biophysical tools in development of oncolytic viruses

Bioprocessing & Manufacture
  • Development of an analytical virology platform to evaluate quality attributes and support process development for oncolytic viruses
  • Development and optimization of a robust set of bioanalytical and biophysical assays to characterize viral particles and their infective potency
  • Design and characterization of a recombinant Newcastle Disease Virus for oncolytic therapy and immune potentiation
12:10
Conference pass

Landscape analysis of RSV vaccine development and how the scientific community view the resent success and failures

Influenza and Respiratory
12:10
Conference pass

Maternal immunity - Its role in vaccination and animal health

Veterinary
Dr Mahesh Kumar, Vice President, Global Biologics Research, Zoetis
12:25
Conference pass

Mucosal Immune Responses in Clinical Studies with Oral Tablet Vaccines for the Prevention of Norovirus or Influenza

Influenza and Respiratory
  • Vaxart’s oral vaccine platform generated substantial neutralizing antibodies to influenza in humans
  • The application of the platform to new respiratory and intestinal targets was begun in 2016
  • Mucosal and systemic immune responses will be discussed from a recently completed Ph1 norovirus vaccine study
12:40
Conference pass

 Developing the next generation of vaccines and monoclonal antibodies using Deceptive Imprinting and Immune Refocusing technology

Immune Profiling
  • Sharing on novel technology that can be employed to develop preventative vaccines, novel immuno-therapeutics and diagnostics in both human and veterinary medicine
  • Exploring the significance of uncoupling immunodominance, antigenic variation and strain-restricted immunity in the development of the next generation immuno-biologicals
12:40
Conference pass

DNA vaccines as cancer therapeutics

Cancer & Immunotherapy
  • Selection of Appropriate Vaccine Antigens for Prostate Cancer
  • Synergy of DNA Vaccines with Checkpoint Inhibitors
  • Three Ongoing Translational Trials of DNA Vaccines in Prostate Cancer
12:40
Conference pass

Design and implementation of clinical trials in an emerging epidemic: Flavivirus Case Study

Emerging Diseases
  • Clinical development challenges associated with the design and conduct of emerging epidemic trials
  • Current status of Zika Vaccine candidates in Clinical Development
  • Geographical Considerations: Epidemiology v Trial Locations
  • Considerations for Zika Vaccine Clinical Development Strategy
12:40
Conference pass

Progress towards a CMV vaccine

Clinical Development April 11
  • Human CMV is implicated in a number of diverse diseases
  • Overview of recent vaccine developments and platforms
  • Preclinical progress towards a Pentamer based vaccine
12:40
Conference pass

Evaluation of Disposable and Single-Use Technologies for Vaccine Production Processes

Bioprocessing & Manufacture
12:40
Conference pass

Success story for alternative influenza platforms: Update on avian influenza vaccines

Veterinary
 
  • Developing poultry vaccines using insect cells
  • Baculovirus system in insect cells for avian influenza in poultry
  • Challenges faced and lessons learnt for future developments
12:40
Conference pass

New fragmentation and solubilization/ stabilization approaches: case study on the influenza

Influenza and Respiratory
  • A new approach for solubilization/stabilization of membrane antigens as well as membrane fragmentation, suitable for novel efficient influenza vaccine development
  • Applications to other highly challenging vaccine candidates
12:55
Conference pass

Results of a PhIa study of M2SR influenza vaccine in healthy adults

Influenza and Respiratory
  • The promise of prevention: A novel universal vaccine virus based on deletion of a portion of the M2 gene
  • Protection from drifted or mismatched flu strains
  • Breadth of protection in multiple age groups
14:40
Conference pass

Innovation and challenges for development and industrialization of vaccines: New technologies, process industrialization and analytics

Bioprocessing & Manufacture
  • Incorporating new technologies
  • Department covering New Biological Entities Process industrialization (Ph III and ownwards) Process and Analytics Life Cycle Management, Manufacturing Support
14:40
Conference pass

Clinical and immunological predictors for lesion regression and viral clearance following HPV immunotherapy

Cancer & Immunotherapy
  • Identification of immunological signatures that predict treatment outcomes with VGX-3100 therapy
  • Implications for cancer immunotherapy with tumor targeted antigens
  • Advancing combinatorial approaches with cancer vaccines that drive antigen specific CD8 T-cells
14:40
Conference pass

Utilizing Human Challenge Studies to Accelerate the Development of Respiratory Vaccines

Influenza and Respiratory
  • Challenge studies provide a controlled environment for addressing crucial questions in vaccine development.  We will discuss our top insights gained from conducting over 45 respiratory viral challenge studies and how we are leveraging these insights in developing vaccines such as the universal flu vaccine ‘FLU-v’.
14:40
Conference pass

The value of adjuvants and vaccines to be used to prevent disease and in post-exposure

Emerging Diseases
  • Using host-directed therapeutics to prevent anti-microbial resistance
  • Mechanisms of the delivery in assisting the immune system to fight reoccurrence
  • Blurring the lines between the therapeutic and preventative nature of vaccines
  • Broadening the immune response using adjuvants for faster and longer-lasting effects
  • Rapid response techniques to contain outbreaks
14:40
Conference pass

Results from a first-in-human study of a wild-type influenza (A/Belgium/4217/2015 H3N2) virus strain as an experimental challenge agent

Clinical Development April 11
  • Ethics of human challenges models
  • How to proceed best without known correlates of protection?
14:40
Conference pass

Utilization of Next Generation Sequencing for selection of vaccine candidates for production animals

Veterinary
 
  • Analyzing full genomic sequences of bacteria isolates
  • Analyzing recombinant HVT vectors
  • Identification of subpopulations
]
15:10
Conference pass

Process development for the production of vaccines and viral vectors in suspension culture of HEK293 cells

Bioprocessing & Manufacture
  • Suspension HEK293 cell line has been scaled up for GMP production of complex vaccines including virus like particles and vectors for high density production under serum-free condition
  • Currently used in clinical trials to develop vaccines
15:10
Conference pass

Development of a novel vaccine for protection against Lyme borreliosis: PhI trial of Valneva’s Lyme vaccine candidate VLA15

Emerging Diseases
  • Supporting evidence from pre-clinical data of protection from Borrelia species pathogenic for humans
  • Product development and public health strategy
15:10
Conference pass

Fc-FcγR interactions of anti-influenza stalk mAbs: Mechanistic data to support universal flu vaccine development

Influenza and Respiratory
  • Studying Fc receptor interactions: How are Abs working to give immunity?
  • Gaining optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies
  • Potential applications to other viruses  
15:10
Conference pass

Novel personalized immune therapies for solid tumors

Cancer & Immunotherapy
  • Rationale for use of immunotherapy in glioblastoma
  • Mobilizing the immune system through patient specific biomarkers, obtained from their tumor
  • Providing a clinical update on the vaccine progress in patients
  • Strategy for design of a Ph III trial immunotherapy trial incorporating lessons learned during Ph II
  • Challenges with manufacturing personalized immunotherapy
15:10
Conference pass

Rational approaches to develop a live attenuated vaccine for African swine fever

Veterinary
15:10
Conference pass

Utilization of technology in the execution of clinical vaccine studies

Clinical Development April 11
Wilhelm (Willie) Muehlhausen, VP eCOA & Innovation, ICON Clinical Research
15:25
Conference pass

Semi-synthetic archaeal lipid adjuvants as platforms for induction of cell-mediated immunity to vaccines

Bioprocessing & Manufacture
  • A novel class of archaeal lipid adjuvants, currently developing a third generation of highly simplified, cost-effective semi-synthetic glycolipid adjuvants
15:40
Conference pass

Yeast-based vaccines: Merging high efficacy, easy antigen combination and advantageous cost of goods

Veterinary
 
  • A novel subunit marker vaccine technology based on milk-yeast
  • New validation data for the technology and vaccines targeting both capsid and enveloped viruses
  • Save >90 % of the manufacturing costs, due to cost effective fermentation, using a single production run for combi vaccines and lacking the need to purify antigens
15:40
Conference pass

Correlates of protection induced by vaccines with emphasis on enteric vaccines

Clinical Development April 11
  • Why are correlates of protection important and how are they determined?
  • Lessons learnt from a collective of vaccine models and studies
  • The need to evaluate the consistency of vaccine production
15:40
Conference pass

VBI-1901: Harnessing Foreign Viral CMV Antigens to Re-Stimulate Anti-Tumor Immunity

Cancer & Immunotherapy
  •  
15:40
Conference pass

Developing new vaccine for H1N1 and H3N2 influenza A viruses

Influenza and Respiratory
  • Advanced development of more effective universal influenza vaccines
  • Using Computationally Optimized Broadly Reactive Antigen (COBRA) - a major step in the right direction towards a universal vaccine
15:40
Conference pass

Technologies to facilitate a rapid vaccine response to newly emerging pathogens

Emerging Diseases
  • With the increasing number of emerging diseases, what technologies and platforms are available to help identify and prevent outbreaks?
  • New vaccines are all moving away from traditional vaccine approaches so how do we choose one platform over another?
  • Being prepared: Promising new platform technologies applicable for vaccine development against emerging pathogens
15:40
Conference pass

Solutions for intradermal administration & clinical experience with the MicronJet600R

Bioprocessing & Manufacture
Glen Zimmermann, Senior Director Business Development, West Pharmaceutical Services
16:40
Conference pass

Sci-B-Vac™: Hepatitis B vaccine Phase III program update

Emerging Diseases
16:40
Conference pass

Influenza virus neuraminidase as target for broadly protective vaccines

Influenza and Respiratory
16:40
Conference pass

Overcoming challenges in seasonal vaccine studies, including maternal immunization

Clinical Development April 11
  • Vaccine development against Clostridium difficile
  • How has the rise an AMR pushed the importance of these infections to immune compromised patients?
Marty Anderson, Executive Director, Clinical Development - GenMed, INC Research
16:40
Conference pass

Oncolytic virus T-VEC shows therapeutic benefit against melanoma after randomized PhIII study

Cancer & Immunotherapy
  • Designing a clinical trial for a new class of drugs – what to test and look for
  • Establishing the legitimacy of oncolytic viruses in cancer therapy, allowing more research in other types of viruses and in approaches where other viral vectors can be combined
  • Taking it outside of melanoma and theoretically to any cancer
16:40
Conference pass

High productivity single-use downstream process for cost-efficient virus manufacturing

Bioprocessing & Manufacture
16:40
Conference pass

ELISpot and FluoroSpot in veterinary vaccine research

Veterinary
 
  • T-cell ELISpot assays and B-cell ELISpot assays in veterinary vaccine research
  • Novel potential of T and B-cell FluoroSpot assays in veterinary vaccine research
  • Why FluoroSpot and not intracellular cytokine staining and Flow cytometry?
16:55
Conference pass

Genetic cancer vaccines for pets: Cutting-edge technologies with high translational potential for humans

Veterinary
 
  • How relevant are preclinical models for developing Cancer Vaccines
  • How to combine new Cancer Vaccines with existing therapies
  • How to achieve local and systemic Cancer control
  • Moving towards innovative products: lessons learnt
16:55
Conference pass

A platform approach for viral vaccine manufacturing

Bioprocessing & Manufacture
  • Our platform approach for the manufacturing of viral vaccines
  • How technological developments help to set-up a robust and scalable process using single use technologies
16:55
Conference pass

Zika Virus-Like Particle (VLP) Based Vaccine

Emerging Diseases
17:10
Conference pass

MVA, viral vector, past, present and future in immune-oncology

Cancer & Immunotherapy
  • Combining our cancer vaccines with checkpoint inhibitors
  • Progress on the new PhII and PhIII trials results
17:10
Conference pass

Immunogenicity of a plant-derived quadrivalent VLP vaccine in adults and the elderly

Influenza and Respiratory
  • Phase 2 clinical results on QIV seasonal VLPs in healthy adults and elderly
  • Comparison of humoral and cell-mediated immune responses induced by VLPs
17:10
Conference pass

An update on the safety, immunogenicity, and efficacy of the rVSVΔG-ZEBOV-GP Ebola Vaccine

Emerging Diseases
  • Further results from three separate clinical trials to  distribute its vaccine by the end of 2017
  • Interim results demonstrated the vaccine’s ability to cut the risk of infection in people
  • Regulatory experience and lessons learned that could help with progressing the Zika outbreak
17:10
Conference pass

A cross-kingdom vaccine against fungal (Candida) & bacterial (Staph aureus) AMR pathogens

Clinical Development April 11
  • First efficacy established for an anti-fungal vaccine: Ph IIa results with NDV-3A
  • US Army collaboration using NDV-3A to prevent Staph aureus skin & soft tissue infections
  • NIH clinical study: Hyper-IgE Syndrome patients with recurrent Candida & Staph infections
17:10
Conference pass

Strategies to effectively support research for clinical trials at the NIAID in response to outbreaks

Bioprocessing & Manufacture
  • Having the ability to interrogate manufacturing data
  • Bringing highly structured data and highly unstructured data together for analysis and aggregation
  • How to analyse production processes that are inherently variable
  • Lessons learned and progress made
17:10
Conference pass

Developing a novel vaccine for therapeutic treatment of cancer in companion animals

Veterinary
 
  • Clinical data demonstrating the progress in adaptive immunotherapy for cancer in companion animals
  • Harnessing the ability of the immune system to eradicate cancer and sharing mode of mechanism
  • Lessons learnt from developing an innovative and patented immunotherapy method to treat cancer in companion animals
Dr Patrick Frayssinet, R&D Director, URODELIA
17:25
Conference pass

Meeting the need for innovative antigen expression systems

Veterinary
 
  • Reengineering expression systems to for improved vaccine development
  • Discussing feasibility of scale-up expression
17:40
Conference pass

Vaccine research, trans-boundary diseases and the biodefence research programme

Veterinary
 
  • Control of highly specially-dangerous pathogens.
  • Developing vaccines engineered for the purpose of control and responding to disease outbreak
Dr cyrilCyril G Gay, Senior National Program Leader, A.R.S. National Programs
17:40
Conference pass

Panel: For vaccines that are being paired with adjuvant or checkpoint blockade therapies, are we working with the right antigenic targets?

Cancer & Immunotherapy
  • What technologies will enable a quick turnaround time for producing personalized vaccine formulations? What delivery systems are supported by the FDA?
  • How will combinational approaches reduce side effects and replace conventional treatments including chemotherapy?
  • Are we leveraging the power of biomarkers that pinpoint which patient subpopulations that would be the ideal candidates for a given immunotherapeutic regimen
  • Using patient’s genetic makeup to design and execute an optimal therapeutic strategy
  • Does the future involve companion diagnostics?
17:40
Conference pass

Use of Disposable Fixed Bed Bioreactor for Propagation of Mammalian Cells

Bioprocessing & Manufacture
  • Capital efficiency for continuous manufacturing techniques and facilities
  • Does the future include smaller players and CMOs?
  • Benefits to vaccine manufacturing and other biologics as we increasingly combine approaches
17:40
Conference pass

Developing vaccines that reach the elderly

Clinical Development April 11
  • Vaccine trials with the elderly pose unique challenges.
  • Misconceptions of vaccines among the elderly.
  • Operational challenges, best practices and innovative techniques that can be put into immediate practice for greater success in working with the elderly in vaccine trials.
17:40
Conference pass

Spike Trimers: A General Vaccine Solution for Beta-coronaviruses

Emerging Diseases
  • Vaccine candidates in development: The current landscape
  • Targeting the MERS-CoV S protein
  • Immunogens based on full-length S DNA and S1 subunit protein elicit robust serum-neutralizing activity against several MERS-CoV strains in mice and non-human primates
17:40
Conference pass

Virospot platform for detection of virus neutralizing antibodies

Influenza and Respiratory
18:10
Conference pass

Facilitated DMAb in vivo delivery for rapid protection from difficult immune targets

Influenza and Respiratory
  • Major improvements in DNA vaccine technology over the past decade has reinvigorated this platform which has conceptual advantages over traditional vaccine platforms and for invivo antigen delivery
  • In humans prior generations of DNA vaccines were poorly immunogenic. Through multiple improvements including synthetic optimization, formulation technology and enhanced EP delivery this technology exhibits improved performance in vivo driving immune responses similar or superior to live viral vectors
  • We have refocused this approach for direct DNA (DMAb) delivery of Monoclonal antibodies targeting EID produced invivo and compare this approach to vaccination for rapid immune protection against important pathogens  
18:10
Conference pass

Vaccine progression and developments against Malaria

Emerging Diseases
  • The first malaria vaccine providing durable protection against infection with malaria parasites
  • PfSPZ vaccine has shown to provide protection against infection with malaria parasites for at least 14 months
  • Next steps to make the vaccine a reality to benefit the huge population still at risk
18:10
Conference pass

Accelerating Vaccine Development & Biomanufacturing Using a Universal, Non-viral Delivery Platform for Engineering of Relevant Cell Types

Bioprocessing & Manufacture
  • Rapidly express mg to gram quantities of MAbs, recombinant proteins, viral vectors, and VLPs
  • Bench to bedside scalability in cells relevant to bioproduction (CHO, HEK, Vero, MDCK, BHK21, insect cells, etc.)
  • Synergize and streamline migration from transient expression to stable cell line generation
18:10
Conference pass

Can we eradicate FMD? An industry perspective

Veterinary
 
  • Global overview of FMD vaccine use
  • Different epidemiological situations, different needs
  • Trends and future evolutions in the FMD vaccine world
  • How vaccine manufacturers contribute to FMD control and eradication
18:10
Conference pass

Development and manufacturing of a nanoparticle HIV vaccine

Clinical Development April 11
2:40
Conference pass

Cancer immunotherapy in oncology biomarker development

Immune Profiling
  • Discussing the curative potential
  • Updates on new developments
  • Challenges faced and steps to overcome these
Dr Mahesh Yadav, Research and Early Development Scientist, Genentech
3:10
Conference pass

Systems analysis of vaccine induced response to enhance correlates of protection of human vaccines

Immune Profiling
 
  • Learn opportunities offered by systems analysis of response to human vaccines and adjuvants to inform rational vaccine development
  • Discussing the significance of new biomarkers in vaccine development
  • Sharing ongoing efforts within EU financed research programmes
Dr Ali M. Harandi, Lab head, Dpt of Microbiology & Immunology, University of Gothenburg
3:40
Conference pass

Designing biomarker strategies for PhI immune phenotyping and profiling

Immune Profiling
  • How to implement biomarkers into Ph I clinical trials
  • Designing biomarker strategies for Ph I immune phenotyping and immune profiling
  • “The Biovacsafe Approach”
Giuseppe Del Giudice, Translational Science Leader, GSK Vaccines
4:40
Conference pass

Analysis of the immune system during infection: Incorporating system serology, clinical trial data and new adjuvant applications

Immune Profiling
5:10
Conference pass

immunoprofiling DENV, Tubercolosis and Pertussis T cell responses in health disease and vaccination

Immune Profiling
 
  • Effectively combining high-throughput sequencing and computational tools to profile T-cells and B-cells for therapeutic developments
  • Discovery of previously unknown human T-cell epitopes that may be key in the initiation of allergic responses, and to the development of biochemical and bioinformatic tools that have been used to map the human T-cell response to a large panel of common allergens
  • Enabling therapeutic development and clinical diagnostics through translation of immune profiling information
5:40
Conference pass

Accelerating innovation with unbiased immunosequencing and somatic mutation profiling

Immune Profiling
  • Unbiased gene amplification method and high-throughput sequencing to profile millions of TCR and BCR
  • Combining Exome/RNA sequencing and computer algorithms to predict neoantigens
6:10
Conference pass

The Human Vaccines Project: Decoding the human immune system to accelerate vaccine development

Immune Profiling
  • Deciphering the human immunome to facilitate vaccine discovery
  • Deciphering the rules of immunogenicity to enable induction of specific and durable protective immune responses
Dr Wayne C Koff, President and CEO - The Human Vaccines Project, International Aids Vaccine Initative Inc

Create your personal agenda –check the favourite icon

09:00
Conference pass

Chair’s opening remarks

Bioprocessing & Manufacture
Bo Arve, Executive Director, Pfizer Vaccine Research
09:00
Conference pass
09:00
Conference pass
09:00
Conference pass

Chair’s opening remarks

Veterinary
Dr cyrilCyril G Gay, Senior National Program Leader, A.R.S. National Programs
09:10
Conference pass

PD-1 Antibodies have the potential to be a broad spectrum antineoplastic treatment both as monotherapy and in combination therapies  

Immune Profiling
  • PD-1 antibodies are checkpoint inhibitors for the treatment of cancer and act by targeted activation of the immune system
  • Initial activity screening was based upon big data analyses of PDL-1 status and mutational burden of various cancers
  • PD-1 antibody therapy appears to be a broad spectrum anticancer monotherapy and has the potential to be foundational in combination therapy
  • Toxicity profiles of checkpoint blockade and combination checkpoint blockade inform treatment options
  • Precision medicine appears to be key in certain tumour types
09:10
Conference pass

Conjugate vaccine discovery and in vitro assays

Bioprocessing & Manufacture
  • Presentation focus on structure function relationship
09:10
Conference pass

How to overcome tumour immunosuppression – Understanding immunosuppression in the microenvironment that leads to anti-tumour activity

Cancer & Immunotherapy
  • Understanding the mechanism that is preventing T-cells from killing cancer cells
  • The important role tumor-induced T reg cells play and development of strategies to overcome this effect
  • Employing anti-CD4 antibody to partially deplete CD4 T-cells
  • Using this method in PhI clinical trials to uncover therapeutic efficacy in a multiple vaccination model
09:10
Conference pass

Scientific challenges and results on developing a new pertussis vaccine

Influenza and Respiratory
  • The need for a new pertussis vaccine with longer lasting immunity
  • Challenges in making an effective pertussis vaccines: Cyclical by nature, waning immunity, asymptomatic carriers
09:10
Conference pass

Shigella vaccine built on GMMA technology – Using outer membrane particles shed from genetically engineered bacteria for cost effective vaccines

Emerging Diseases
  • The potential impact and cost-effectiveness of a Shigella vaccine in developing countries
  • Potential of the GMMA technology in vaccine strategies targeting poverty related diseases
09:10
Conference pass

Developing new standards for building trust with pharmaceutical companies: A reflection on GlaxoSmithKline’s (GSK’s) journey

Partnerships April 12
  • Changing the standard ways of working that industry uses with its academic and public health customers
  • How to become a trusted partner in the scientific and public health community to deliver the best quality of healthcare to patients
  • Changing the standard ways of working that industry uses with its academic and public health customers
  • How to become a trusted partner in the scientific and public health community to deliver the best quality of healthcare to patients
 
09:10
Conference pass

Investigational HDM-mLAMP-Vax DNA Vaccines for Canine Atopic Dermatitis Induce Robust Th1 Immune Responses in Mice and Dogs

Veterinary
 
  • Lysosomal Associated Membrane Protein (LAMP) is a major component of lysosomes
  • Investigational LAMP-Vax DNA vaccines are thought to utilize the intracellular localization of LAMP to bring antigens to MHC-II
  • LAMP-Vax DNA vaccines induce robust Th1 responses in multiple animal models of human allergic diseases
  • LAMP-Vax DNA vaccine was tested in a Phase I clinical study for Japanese red cedar for allergy and met its safety endpoints.
  • HDM-mLAMP-Vax vaccines encode two major allergens for Canine Atopic Dermatitis (CAD)
  • HDM-mLAMP-Vax vaccines induce Th1-skewed humoral and cellular immune response in mouse model for CAD
  • Immunogenicity of the HDM-mLAMP-Vax vaccines has been confirmed in dogs
09:40
Conference pass

Addressing the unmet need for therapeutic vaccines for autoimmune conditions with emphasis on arthritis

Immune Profiling
 
  • Exploring the current landscape for vaccine therapeutics for autoimmune conditions
  • Sharing updates, mode of mechanisms, and progress regarding development of a vaccine for Rheumatoid arthritis
09:40
Conference pass

Bioconjugation technology for the next generation of conjugate vaccines: Recent improvements, CQAs, and analytics method development

Bioprocessing & Manufacture
  • Technology advantages and opportunities
  • Focus on development and characterization of bioconjugate vaccine candidates
  • Discussion of CQAs based on preclinical and clinical POC data
09:40
Conference pass

Interactive discussion: Using the recent license of Cholera vaccine as a case study

Emerging Diseases
  • Single-dose live oral cholera vaccine shown to protect cholera in protection in a human cholera challenge model
  • Lessons learned from the regulatory approval that may be applicable to other vaccines
  • Next steps to have this available for children and for use outside of the US
09:40
Conference pass

Disease modifying vaccines in Chronic Obstructive Pulmonary Disease (COPD)

Influenza and Respiratory
-          Presenting early stage development of a vaccine to prevent the bacterial infections that exacerbate COPD
-          COPD is a very common, chronic, progressive, respiratory illness of adults, which can be triggered by bacterial infections
-          A vaccine to prevent these respiratory infections could modify the clinical progression of COPD, and improve quality of life
09:40
Conference pass

Translating cancer vaccines from mice to human clinical trials

Cancer & Immunotherapy
09:40
Conference pass

New fragmentation and solubilization approaches toward bacterial and viral vaccines

Veterinary
  • A proprietary surfactant and detergent based approach consisting either on membrane splitting and/ or solubilization and stabilization
  • Presenting protection to commercialized influenza vaccines but using up to 30 times less antigens in one vaccine dose
  • Results from a bacterial vaccine against leptospirosis
09:55
Conference pass

Ancer™: An immunoinformatic platform for personalized cancer vaccine delivery

Partnerships April 12
09:55
Conference pass

Effectively transitioning from vaccine research to commercial production.  The adjuvanted DNA vaccine example from Agrilabs.

Veterinary

 
10:10
Conference pass

Process Development, Scale-up and COG of conjugate vaccines

Bioprocessing & Manufacture
 
  • Presentation on Scale-up commercial manufacturing and challenges
  • Impact on COGS
  • Incl. Classical and modern  conjugation reactions
10:10
Conference pass

Characterization of a novel personalized cancer immunotherapy: A best-in-class adenosine A2A receptor antagonist optimized for high potency in adenosine-rich tumor microenvironment

Immune Profiling
  • Targeting a new immune-checkpoint in cancer
  • Characterization of the immune mechanism of action a novel immune checkpoint blocker
  • Translational strategy to improve the antitumor efficacy in patients
10:10
Conference pass

Can understanding antiviral immunity induced by oncolytic viruses predict their success as a tumor immunotherapy?

Cancer & Immunotherapy
  • Oncolytic viruses as immunotherapy: progress and remaining challenges
  • How do we restrain antiviral immune responses and minimize pathology while promoting antitumor immunity to override immune tolerance?
  • Combining OV therapy with chemo- and immune-based therapeutic regimens and the risks
10:10
Conference pass

The Multiple Antigen Presenting System: A platform for novel vaccines that elicit B- and Th1/Th17-cell responses

Influenza and Respiratory
  • Are the current serotypes in the vaccine enough protection?
  • How can we measure and predict this?
  • Comparing cross protection with other vaccine candidates
10:10
Conference pass

Demonstrating the safety and efficacy profile of an alternative adjuvant delivery system against influenza

Partnerships April 12
10:10
Conference pass

A platform approach to address AgroBiosecurity

Veterinary
10:25
Conference pass

Tools to assess and advance Group A Streptococcus Vaccines

Emerging Diseases
 
  • Assembly and genome sequencing of a representative strain panel 
  • Economic analysis of vaccine implementation in Australia and New Zealand, compared to other public health initiatives
  • Development of a reference assay
  • A clinical development plan to move forward with
10:25
Conference pass
11:30
Conference pass

NasoShieldTM anthrax vaccine candidate provides protection from challenge and rapid immunogenicity following a single intranasal dose

Influenza and Respiratory
  • The currently licensed anthrax vaccine requires 3 administrations for protection
  • NasoShield demonstrates single dose protective efficacy in preclinical models of inhalation anthrax
  • Preclinically, the protective antibody response to NasoShield had faster onset and was more persistent than the licensed vaccine
  • A first in man, Phase 1 safety and immunogenicity study is planned for Q42017
11:30
Conference pass

Self-antigen T-cell vaccines for the treatment and prevention of breast and ovarian cancers

Cancer & Immunotherapy
 
  • Integrating different cancer vaccine types and check point inhibitors in combinational approaches
  • Augmenting CD4 helper T-cell immunity using peptide epitopes
11:30
Conference pass

Paratyphoid A fever & vaccine development: The importance of vaccines with the rise of antibiotic resistance

Emerging Diseases
 
  • Role of vaccines as a part of an integrated program to combat the spread of antibiotic resistance 
  • The need for a more effective Typhoid vaccine and an adequate supply needed to meet demand, particularly in the most affected countries
  • Overview of the promising candidates in the pipeline
Dr Akshay Goel, Senior Vice President - R&D, Biological E. Limited
11:30
Conference pass

Global and localized drug product supply chain

Bioprocessing & Manufacture
 
  • Modular drug product production
11:30
Conference pass

Strategies for effective clinical trial design for combinational immunotherapies

Immune Profiling
11:30
Conference pass

Investor panel: Hear from a number of VCs to better understand what they are looking for before they invest

Partnerships April 12
More panellists to join shortly
Stephen Nagler, Executive Director, MedPro Investors LLC
Sonny Saksena, Managing Director, Mahir Capital Strategies
Dr Misha Petkevich, Chief Investment Officer, V2M Capital LLC
11:40
Conference pass

Developing a safe and effective Porcine Epidemic Diarrhea (PEDv) vaccine

Veterinary
Prof Volker Gerdts, Professor of W.C.V.M. and Associate Director of Research, Vaccine and Infectious Disease Organizatio, VIDO-InterVac
12:00
Conference pass

Tuberculosis vaccine R&D: Addressing a global epidemic

Influenza and Respiratory
 
  • New insights into why immunity from BCG vaccine is so variable
  • Paving the way we develop new TB vaccines
  • Identify immune correlates that could facilitate TB vaccine development
12:00
Conference pass

Comprehensive profiling of T cell responses to putative neoantigens reveals smarter targets for cancer immunotherapy

Cancer & Immunotherapy
  • ATLAS™ is a clinically-proven platform that can comprehensively characterize the specificity and quality of HLA-diverse human T cell responses
  • T cell neoantigens identified using ATLAS are often missed by algorithms
  • Inhibitory neoantigens are emerging that could not be predicted in silico
  • ATLAS T cell profiles predict response to checkpoint blockade therapy
12:00
Conference pass

Strategies for developing vaccines against ETEC

Emerging Diseases
The need for an ETEC vaccine and the current landscape of candidates  will be reviewed.  This will be followed by an in depth analysis of the most advanced of these candidates, ETVAX, an inactivated whole cell vaccine which PATH is developing in collaboration with Scandinavian BioPharma. This product exceeded its primary endpoints in a phase 1 trial in Finnish volunteers and is currently being evaluated in a descending age study in Bangladesh.  It is being administered with and without the mucosal adjuvant dmLT.  It may in the future be combined with a vaccine candidate for Shigella.
12:00
Conference pass

Glycoconjugate vaccine technology from a regulatory perspective

Bioprocessing & Manufacture
12:00
Conference pass

Immune-Engineering Therapeutic Vaccines: Removing T-reg epitopes in Cancer Immunotherapy, Adding T-reg epitopes for Inducing Tolerance in Autoimmunity

Immune Profiling
  • Using state-of-the art immunoinformatics tools, EpiVax have uncovered ‘networks’ of T cell epitopes that activate Tregs and down-regulate immune responses
  • These Treg epitopes can be found in tumor associated antigens and in the vaccine antigens of human pathogens; engineering the Treg epitopes out appears to enhance vaccine efficacy
  • Engineering Treg epitopes into tolerance inducing strategies for autoimmunity and allergy is an approach that EpiVax is pursuing as well. This presentation will describe the impact of immune engineering in therapeutic vaccines
12:00
Conference pass

Eradicating Porcine Cysticercosis with a novel vaccine containing the TSol 18 protein

Veterinary
 
  • Global clinical trials demonstrating the efficacy of the vaccine in protecting pigs against T.solium
  • Recombinant vaccine containing TSol 18 protein licensed for commercial use for first time in the world
  • Exciting eradication potential and lessons learnt from development challenges faced
13:30
Conference pass

UBER Vaccinology:  A new operational and funding paradigm for vaccine innovation

Partnerships April 12
  • Publically funded, not-for-profit model to de-risk vaccine development to meet public health needs and industry thresholds
  • Effective leveraging of funding through networks and partnerships
  • Fostering partnerships to drive vaccine innovation
  • Attaining self-sustainability in a not-for-profit organization
 
Dr Luis H. Martin, Chief Executive Officer, Pan-Provincial Vaccine Enterprise Inc. (PREVENT)
13:40
Conference pass

The eradication of Polio: Have we succeeded?

Keynotes

-    Measuring and monitoring the success of eradication
-    End game and strategic plan
-    What’s next? Can we eradicate measles?
 
14:00
Conference pass

Areas of interest for big pharma: External collaborative research and partnering opportunities for vaccine development

Partnerships April 12
14:10
Conference pass

A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria

Keynotes

-    Recommendations from the National Vaccine Advisory Committee
-    Use of vaccines to prevent the infections that could or have developed AMR to antibiotics, in adjunction to antibiotic stewardship
-    Examples in Haemophilus influenza, Streptococcus, Staphylococcus aureus

 
14:30
Conference pass

Support mechanisms to develop vaccines with better effectiveness: Why does the effectiveness of the rotavirus vaccine drop in middle to low income countries?

Partnerships April 12
 
  • What vaccines are the NIH prioritizing and why?
  • How could we increase the efficacy of existing vaccines and why does it drop in low to middle income countries?
  • How to access government funding for vaccine development programs
14:40
Conference pass

Panel: How much efficacy is enough? What are the implications of a vaccine no longer being a replacement technology but a companion technology?

Keynotes

-    The concept of partially protected vaccines like malaria, TB, NTDs where the clinical efficacy is no longer 85/90% but closer to 40% 
-    Future of vaccine development 
-    The combining drivers of technology and emerging diseases

More panelists to be announced shortly
15:00
Conference pass

Vaccine Preservative: Thimerosal- mitigating crucial demand and supply issue for global vaccine supplies

Partnerships April 12